Skip to main content

Table 6 G6PDd prevalence and primaquine policy

From: Malaria in Brazil, Colombia, Peru and Venezuela: current challenges in malaria control and elimination

Country

Estimated G6PDd for common variants (mostly A −)

PQ use

PQ as DOT?

G6PD testing required for PQ administration

Brazil

>3–7% [132]

0–12.9% [133]

P. falciparum and P. vivax

No

No-currently under consideration and expected to be recommended when possible with follow-up of possible PQ-induced haemolysis G6PDd cases to be treated with PQ at 0.75 mg/kg/week for 8 weeks

Colombia

>3–7% [132]

1.4–15.4% [133]

6.56% [135]

P. vivax

No

No

Peru

>0–1% [132]

0–0.7% [133]

P. falciparum (since 2015) and P. vivax

Yes

No

Venezuela

>7–10% [132]

0–3.5% [133]

3.6% [134]

P. falciparum and P. vivax

No

No

  1. PQ and G6PD testing policies taken from [1]
  2. P. vivax: Plasmodium vivax; P. falciparum: Plasmodium falciparum; DOT: directly observed treatment; PQ: primaquine. PQ is contraindicated in infants and pregnant and breastfeeding women